London, 18th December 2023 - Kadans Science Partner (“Kadans”) has added a new asset in King’s Cross, London, UK to its Pan-European portfolio. The new asset at 22-23 Tileyard Road will be delivered as purpose built, high-quality laboratory accommodation, providing much needed technical real estate to the King’s Cross and London market. The asset was acquired from City & Provincial Properties. This latest acquisition continues to grow Kadans’ footprint in the Knowledge Quarter, London, a global centre of excellence for science & technology innovation.

The Knowledge Quarter Kings Cross is a consortium of over 75 academic, cultural, research, scientific and media organisations large and small from The Francis Crick Institute and University College London (UCL) to the Wellcome Trust, Google, GSK, Merck (MSD) and AstraZeneca.

The acquisition quickly follows the successful planning application of 4 Brandon Road. Following the acquisition, it will see Kadans deliver over 350,000 sq ft of purpose-built laboratory space in London’s Knowledge Quarter. Kadans’ first building in the cluster is 5-10 Brandon Road delivering in April 2024 and will provide a mixture of cleanrooms, laboratory and office accommodation.

James Sheppard, Managing Director (UK & Ireland), Kadans Science Partner said: ‘Kadans’ continued growth in London showcases our unwavering confidence in the London market. Following on from our successful planning application at 4 Brandon Road we are pleased to be delivering more space in one Europe’s most important innovation clusters. With 5-10 Brandon Road completing in March 2024, we will provide a pipeline of purpose-built laboratory space to allow London’s SMEs to keep growing and remain the capital.’

Paul Kempe, Managing Director, City and Provincial said: This disposal represents an important step in City and Provincial’s industrial strategy, strengthening our balance sheet and providing additional dry powder to continue our pivot to self-storage. Our commitment to expanding our unique creative community within Tileyard Studios and Tileyard North is unaffected by the sale.

With these two new acquisitions in London, the Kadans portfolio now comprises of over 60 buildings and numerous projects under development in the Netherlands, England, Scotland, Belgium, France, Germany and Spain. Kadans aspires to partner with universities, venture capital firms and organisations to create strong knowledge-sharing ecosystems of science and innovation across Europe.

Kadans was advised by Gerald Eve (agency) and Mills & Reeve (legal) on the acquisition of 22-23 Tileyard. CPP was advised by JLL (agency) and Shoosmiths (legal) on the sale.

------------------------------------------------------------------------------

Notes to Editor

Kadans Science Partner is the European leader investing in the development of ecosystems and real estate with a dedicated focus on knowledge-intensive sectors. We focus on bringing people together to overcome global challenges. Therefore, we invest, develop and operate specialised assets to complement science clusters. Across Europe, we have built a network of clients, partner organisations, and innovative minds, active in Life Sciences & Health, Food, Energy & Digital Economy. All determined to find solutions to the global challenges we face today. Currently already active in 25+ science clusters, our network continues to grow as we develop more locations and support more clusters across Europe.